Deoxycoformycin for Mature T-Cell Leukaemias
Author Information
Author(s): C. Dearden, E. Matutes, D. Catovsky
Primary Institution: Royal Marsden Hospital and Institute of Cancer Research
Hypothesis
What is the therapeutic activity of deoxycoformycin in treating mature T-cell leukaemias?
Conclusion
Deoxycoformycin is a useful therapy for T-cell leukaemias, especially for Sezary syndrome and T-PLL.
Supporting Evidence
- Overall response rates were 38%, with variations according to diagnosis.
- Best responses were seen in CTCL, particularly in Sezary patients.
- Responses in T-PLL were recorded in 48%, including three complete responses.
- Fifteen percent of responses were seen in ATLL, with responders having prior chemotherapy.
Takeaway
This study tested a medicine called deoxycoformycin on patients with a type of blood cancer, and it helped some of them feel better.
Methodology
DCF was given intravenously at 4 mg/m2 weekly for the first 4 weeks and then every 2 weeks until maximal response.
Limitations
The study does not show a radical change in the natural history of aggressive T-cell disorders with DCF alone.
Participant Demographics
Median age was 54 years, with a range of 20-81 years; 59% had prior systemic treatment.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website